1. PDE5 inhibitor sildenafil in the treatment of heart failure: A meta-analysis of randomized controlled trials 
Xiao-Dong Zhuang, Ming Long, Fei Li, Xun Hu, Xin-Xue Liao, Zhi-Min Du 
International Journal of Cardiology 
Volume 172, Issue 3, Pages (April 2014)
DOI: /j.ijcard
Copyright © 2014 Elsevier Ireland Ltd Terms and Conditions

2. Fig. 1 Flow diagram of the study selection process.
International Journal of Cardiology  , DOI: ( /j.ijcard )
Copyright © 2014 Elsevier Ireland Ltd Terms and Conditions

3. Fig. 2
Pooled relative risk and mean difference in the outcome of advance events (A), 12-month peak VO2 (B) in the substudies considering sildenafil compared to placebo therapy between EFrHF and EFpHF patients.
International Journal of Cardiology  , DOI: ( /j.ijcard )
Copyright © 2014 Elsevier Ireland Ltd Terms and Conditions

4. Fig. 3
Pooled mean difference in the outcome of VO2 at AT (A), VE/CO2 slope (B), LV ejection fraction (C) in the studies considering sildenafil compared to placebo therapy in HF patients.
International Journal of Cardiology  , DOI: ( /j.ijcard )
Copyright © 2014 Elsevier Ireland Ltd Terms and Conditions

5. Fig. 4
Pooled mean differences in the outcome of heart rate (A), systolic blood pressure (B), diastolic blood pressure (C) and pulmonary systolic pressure (D) in the studies considering sildenafil compared to placebo therapy in HF patients.
International Journal of Cardiology  , DOI: ( /j.ijcard )
Copyright © 2014 Elsevier Ireland Ltd Terms and Conditions

6. Fig. 5
Pooled mean difference in the outcome of emotional function (A), fatigue (B), and breathlessness (C) in the studies considering sildenafil compared to placebo therapy in HF patients.
International Journal of Cardiology  , DOI: ( /j.ijcard )
Copyright © 2014 Elsevier Ireland Ltd Terms and Conditions